Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.34 USD
+0.08 (6.35%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.31 -0.03 (-2.24%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLSD 1.34 +0.08(6.35%)
Will CLSD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Other News for CLSD
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Director Anthony Gibney Acquires 100,000 Shares of Clearside Biomedical Inc (CLSD)
Video: Friday 4/19 Insider Buying Report: CLSD, ULS
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Clearside Biomedical Welcomes Anthony Gibney to Board